AZN240816P81000
- 0.40
- +0.10+33.33%
AstraZeneca Newsroom
AstraZeneca's U.K. Vaccine Facility at Risk Due to Government Aid Cuts, FT Reports
AstraZeneca Imfinzi/Lynparza Combo Granted EU Approval
AstraZeneca's New £450m UK Vaccine Hub Under Threat From Reeves' State Aid Review
China Approves AstraZeneca-Daiichi Sankyo's Gastric Cancer Therapy
AstraZeneca Wins EU Approval for Recurrent Endometrial Cancer Treatment
AstraZeneca PLC (LON:AZN) Shares Could Be 49% Below Their Intrinsic Value Estimate
Global Equities Roundup: Market Talk
AstraZeneca Becomes First U.K. Company to Hit 200 Billion-Pound Valuation -- Market Talk
Struggling COVID-19 Vaccines From AstraZeneca, BioNTech/Pfizer, Moderna Cut Incidence Of Arterial Thromboses That Cause Heart Attacks, Strokes, British Study Shows
New European Regulations Could Hinder Rare Disease Treatments, Pharma Industry Raises Concerns Over Stricter Clinical Trial Rules
Long Covid Remains Diagnostic Mystery, Diagnosis Remains Elusive; National Institutes of Health-Funded Study Shows
AstraZeneca (AZN) Receives a Sell From UBS
Seaport Therapeutics Appoints David Wheadon, M.D., to Its Board of Directors
Yuhedian is approved for use in previously treated HER2-positive advanced or metastatic gastric cancer patients.
Based on the clinical results of DESTINY-Gastric06, trastuzumab deruxtecan can provide clinically significant benefits to patients. Shanghai, August 13, 2024 / PRNewswire / - On August 5, 2024, Enhertu (trastuzumab deruxtecan for injection), jointly developed and commercialized by AstraZeneca and Daiichi Sankyo, was conditionally approved by the Chinese National Medical Products Administration (NMPA). This product is suitable for monotherapy for the treatment of locally advanced or metastatic HER2-positive adult gastric or
AstraZeneca, Daiichi Sankyo's Gastric Cancer Drug Secures Conditional Nod in China
AstraZeneca Announced Enhertu Approved In China For Patients With Previously Treated HER2-Positive Advanced Or Metastatic Gastric Cancer
Enhertu Approved in China for Patients With Previously Treated HER2-positive Advanced or Metastatic Gastric Cancer
AstraZeneca Price Target Raised to $95.00/Share From $90.00 by TD Cowen
AstraZeneca Analyst Ratings
AstraZeneca Hits 17-month High